+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2020

  • ID: 5007663
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 880 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Cellectis SA
  • Gilead Sciences Inc
  • Merck & Co Inc
  • Rich Pharmaceuticals Inc
  • MORE
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma - Pipeline Review, H1 2020, provides an overview of the Hodgkin Lymphoma (Oncology) pipeline landscape.

Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Hodgkin Lymphoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 1, 42, 40, 1, 15, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 6, 2, 1, 3 and 1 molecules, respectively.

Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Cellectis SA
  • Gilead Sciences Inc
  • Merck & Co Inc
  • Rich Pharmaceuticals Inc
  • MORE
  • Introduction
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Overview
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Development
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Assessment
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Companies Involved in Therapeutics Development
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Drug Profiles
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by AbbVie Inc, H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Actinium Pharmaceuticals Inc, H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by ADC Therapeutics SA, H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Affimed GmbH, H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Agios Pharmaceuticals Inc, H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H1 2020 (Contd..4), H1 2020
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • AbbVie Inc
  • Actinium Pharmaceuticals Inc
  • ADC Therapeutics SA
  • Affimed GmbH
  • Agios Pharmaceuticals Inc
  • AlfaSigma SpA
  • Alissa Pharma
  • Angiocrine Bioscience Inc
  • Anhui Anke Biotechnology (Group) Co Ltd
  • Apollomics Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Aurigene Discovery Technologies Ltd
  • Avipep Pty Ltd
  • Bayer AG
  • Biohaven Pharmaceutical Holding Company Ltd
  • Bristol-Myers Squibb Co
  • Carrick Therapeutics Ltd
  • Catalent Inc
  • Cell Medica Ltd
  • Celldex Therapeutics Inc
  • Cellectar Biosciences Inc
  • Cellectis SA
  • Celleron Therapeutics Ltd
  • Cellestia Biotech AG
  • Cellular Biomedicine Group Inc
  • Celularity Inc
  • Checkmate Pharmaceuticals Inc
  • Checkpoint Therapeutics Inc
  • Chipscreen Biosciences Ltd
  • Constellation Pharmaceuticals Inc
  • CSL Ltd
  • CStone Pharmaceuticals Co Ltd
  • Curis Inc
  • Eutilex Co Ltd
  • Faron Pharmaceuticals Oy
  • Gibson Oncology LLC
  • Gilead Sciences Inc
  • Harbin Gloria Pharmaceuticals Co Ltd
  • Hebei Senlang Biotechnology Inc Ltd
  • Helocyte Biosciences Inc
  • HRAIN Biotechnology Co Ltd
  • Immune Cell Inc
  • Immunomedics Inc
  • Incuron LLC
  • Incyte Corp
  • Inhibrx Inc
  • Magenta Therapeutics Inc
  • Marker Therapeutics Inc
  • Merck & Co Inc
  • Merck KGaA
  • Millennium Pharmaceuticals Inc
  • Miltenyi Biotec GmbH
  • NantKwest Inc
  • NewBio Therapeutics Inc
  • Northlake International LLC
  • OncoTartis Inc
  • Protheragen Inc
  • RAPT Therapeutics Inc
  • Regeneron Pharmaceuticals Inc
  • Rhizen Pharmaceuticals SA
  • Rich Pharmaceuticals Inc
  • Rizen (Suzhou) Biosciences Co Ltd
  • Sanofi
  • Seattle Genetics Inc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • Shanghai Pharmaceutical Group Co Ltd
  • Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
  • Shattuck Labs Inc
  • Sichuan Kelun Pharmaceutical Co Ltd
  • SpecificiT Pharma Inc
  • Stemline Therapeutics Inc
  • Syndax Pharmaceuticals Inc
  • Tacitus Therapeutics Inc
  • TaiGen Biotechnology Co Ltd
  • Taiwan Liposome Co Ltd
  • Tessa Therapeutics Pte Ltd
  • Trillium Therapeutics Inc
  • Tyme Technologies Inc
  • Viracta Therapeutics Inc
  • Wuhan Bio-Raid Biotechnology Co Ltd
  • Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll